Prognostic value and multifaceted roles of tetraspanin CD9 in cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F23%3A00571537" target="_blank" >RIV/68081707:_____/23:00571537 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14310/23:00131079 RIV/61989592:15110/23:73619898 RIV/00098892:_____/23:10157997 RIV/00159816:_____/23:00079605

Výsledek na webu

<a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1140738/full" target="_blank" >https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1140738/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fonc.2023.1140738" target="_blank" >10.3389/fonc.2023.1140738</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic value and multifaceted roles of tetraspanin CD9 in cancer

Popis výsledku v původním jazyce

CD9 is a crucial regulator of cell adhesion in the immune system and plays important physiological roles in hematopoiesis, blood coagulation or viral and bacterial infections. It is involved in the transendothelial migration of leukocytes which might also be hijacked by cancer cells during their invasion and metastasis. CD9 is found at the cell surface and the membrane of exosomes affecting cancer progression and therapy resistance. High expression of CD9 is mostly associated with good patients outcome, with a few exceptions. Discordant findings have been reported for breast, ovarian, melanoma, pancreatic and esophageal cancer, which might be related to using different antibodies or inherent cancer heterogeneity. According to in vitro and in vivo studies, tetraspanin CD9 is not clearly associated with either tumor suppression or promotion. Further mechanistic experiments will elucidate the role of CD9 in particular cancer types and specific conditions.

Název v anglickém jazyce

Prognostic value and multifaceted roles of tetraspanin CD9 in cancer

Popis výsledku anglicky

CD9 is a crucial regulator of cell adhesion in the immune system and plays important physiological roles in hematopoiesis, blood coagulation or viral and bacterial infections. It is involved in the transendothelial migration of leukocytes which might also be hijacked by cancer cells during their invasion and metastasis. CD9 is found at the cell surface and the membrane of exosomes affecting cancer progression and therapy resistance. High expression of CD9 is mostly associated with good patients outcome, with a few exceptions. Discordant findings have been reported for breast, ovarian, melanoma, pancreatic and esophageal cancer, which might be related to using different antibodies or inherent cancer heterogeneity. According to in vitro and in vivo studies, tetraspanin CD9 is not clearly associated with either tumor suppression or promotion. Further mechanistic experiments will elucidate the role of CD9 in particular cancer types and specific conditions.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in Oncology

ISSN

2234-943X

e-ISSN

2234-943X

Svazek periodika

13

Číslo periodika v rámci svazku

MAR 17 2023

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

11

Strana od-do

1140738

Kód UT WoS článku

000961544200001

EID výsledku v databázi Scopus

2-s2.0-85152578989